Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results ...
PharmiWeb

Prostate Cancer Diagnostics Market: PSA Tests will Continue to be the Largest Adopted Tests for Diagnosis with Keyplayers Abbott Laboratories, AstraZeneca plc.

According to the latest report by Fact.MR, the global prostate cancer diagnostics market is anticipated to exhibit a steady expansion at 5.3% CAGR during the forecast period 2017 to 2022. In terms of ...